U
FLNA

UBS’s Filana Therapeutics FLNA Stock Holding History

UBS’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-714
Closed -$29K – 10697
2014
Q2 		$29K Sell
714
-15,372
-96% -$569K ﹤0.01% 7598
2014
Q1 		$620K Buy
+16,086
New +$568K ﹤0.01% 4003
2013
Q3 		– Sell
-2,829
Closed -$49.5K – 10661
2013
Q2 		$44K Buy
+2,829
New +$59.8K ﹤0.01% 6890

Other funds holding FLNA

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
MSP
Madison Street Partners Denver, Colorado $3.05M AUM 5.94% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

UBS's FLNA Position: Q3 2014 in Review

UBS sold out of Filana Therapeutics (FLNA) in Q3 2014, closing a stake of 714 shares — an estimated $29K sold.

UBS first reported a position in FLNA in Q2 2013 and held it in 3 quarters. The position peaked at $620K in Q1 2014. 73 funds tracked by Wall St. Rank hold FLNA as of Q3 2014.

  • UBS reported no remaining Filana Therapeutics position as of Q3 2014 after selling out during the quarter.
  • UBS sold 714 Filana Therapeutics shares in Q3 2014, an estimated $29K.
  • UBS first reported a position in Filana Therapeutics in Q2 2013 and held it in 3 quarters.
  • UBS's Filana Therapeutics position peaked at $620K in Q1 2014.
  • 73 funds tracked by Wall St. Rank held Filana Therapeutics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.